It is approved as a first-line, stand-alone medication, or monotherapy, along with diet and exercise to improve glycemic control in adults with type 2 diabetes. BYETTA is also approved as an adjunctive therapy to improve glycemic control in patients
Amylin Pharmaceuticals Inc Reports Operating Results
Related posts:
- Lilly Reports Second Quarter 2011 Results The US Food and Drug Administration (FDA) approved Tradjenta(TM) (linagliptin),...
- Amylin Pharmaceuticals Drugs Approved By The EU Diabetes To Fix Diabetic Nerve Damage, Blood Vessels And Support Cells...
- Type II Diabetes Patients Improve Glycemic Control In Dapaglifozin The data from three stage randomized controlled clinical trials that...
- Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly In 2002, Amylin entered an alliance with Lilly for the...
- ChemoCentryx Reports CCX140 A Novel Oral CCR2 Antagonist Demonstrates These data were presented today in San Diego at the...